Pain · Regulatory

Our CE mark sits in the footer. US procurement reads that as a red flag. What now?

The CE mark is real. The compliance is real. The US reader treats its presence without a US equivalent claim as evidence the firm has not seriously entered the US regulatory frame. The mark is right. The placement is the problem.

FLAG.

Six signals the regulatory posture is reading as not-yet-US-ready.

  • The "are you cleared for US?" question that does not go away. The US prospect, in the second or third call, asks whether the product has FDA, NRTL, FCC, or FedRAMP, depending on vertical. The team answers yes-with-caveats. The prospect reads the caveat as a no.
  • The legal-team review that adds six weeks to every deal. US buyer's counsel reviews the product page, sees CE in the footer, sees no US equivalent named, and routes the deal through an extended product-liability review. The German firm reads the delay as US bureaucracy. The delay is the sort.
  • The hospital buyer that asks for the 510(k) number. The medical-device prospect asks for the 510(k) clearance number on the demo call. The product has MDR 2017/745 CE marking under the EU regime and is awaiting US filing. The prospect goes quiet.
  • The federal RFP that cuts on absent FedRAMP or CMMC. The SaaS or defense-adjacent IT firm submits a strong technical response. The cover-sheet check shows no FedRAMP authorization-to-operate and no CMMC posture. Round one cuts.
  • The product page that runs every European certification and nothing US. CE, RoHS, REACH, GS, GDPR, ISO 13485. The page reads complete in the EU register and unfinished in the US register. Same product, different reader, opposite verdict.
  • The product-liability quote that lands at three times the European premium. US product-liability insurance is priced on US compliance evidence. A product with EU-only compliance documentation gets priced as untested in the US tort frame. The premium reads as a risk signal upstream of the buyer.
!
Attention

If the US buyer asks for the 510(k), the NRTL listing, the FedRAMP ATO, or the CMMC posture and the answer is "we have CE and equivalent EU certifications," the buyer is mapping the gap. The gap closes the deal.

Two regulatory frames. No common conversion table.

The EU and US regulatory frames are not interchangeable. CE marking under the EU New Legislative Framework declares conformity to a set of EU directives or regulations. It is a self-declared mark in many product categories and a notified-body-certified mark in others. The mark says the product meets EU rules.

The US frame asks a different question, vertical by vertical. Does the medical device have a 510(k) clearance number issued by FDA? Does the workplace electrical equipment have a Nationally Recognized Testing Laboratory listing on the OSHA NRTL list? Does the radio equipment have an FCC ID under FCC Part 15? Does the chemical have an EPA registration where required? Does the federal cloud service have a FedRAMP Authorization to Operate? Does the defense-adjacent IT system meet CMMC Level 2 or 3 with the relevant NIST SP 800-171 controls? Does the export-controlled item carry an ITAR or EAR classification on file?

None of these answers is the CE mark. The CE mark is a signal of engineering and quality-system discipline that the US frame treats as adjacent, not equivalent. A US buyer reading a product page with CE in the footer and no US-side claim reads the priority order off the page: EU first, US second, US-readiness incomplete. The buyer is not penalising the mark. The buyer is pricing the absence of the US-side claim.

US REGULATORY PRESENTATION: WHAT MOVES CE ONLY FOOTER MARK US PATH STATUS NAMED PAIRED EU + US FRAME
What changes in the file: CE moves from a footer mark to a paired EU/US posture with status named for the buyer.

This effect compounds in regulated SaaS, defense-adjacent IT, medical devices, industrial electrical, and chemicals. The vertical-specific US frame is unforgiving. Firms in AI-touching product lines may also need to declare EU AI Act posture alongside the US AI deployment posture. The US buyer reading both frames at once expects both to be named.

Round-one volume helps the math. In federal IT alone, the gap shows up in round one nearly every time: no FedRAMP ATO, no CMMC posture, cut. The capability never gets read.

?
Open question

Pull the product page. Above the fold, is there a named US framework with a status declared (registered, in process, planned, not applicable with reason)? If no, the US reader is making the sort on absence, and the absence is not the absence of work, it is the absence of communication.

"The CE mark is correct. The placement says EU is primary and US is incomplete. The buyer reads the placement before they read the product."House reading

Wrong placement is paid in cut bids, slow deals, and inflated premiums.

The Real Cost.

  1. Cut bids. Federal and federal-adjacent RFPs can cut the response before the technical evaluator reads it when the US framework is absent.
  2. Slow deals. US enterprise deals slow down because product-liability counsel cannot map CE to a US-side claim. Cycle stretches and competitor catches up.
  3. Insurance premium. US product-liability underwriting prices the absence of US-side compliance evidence as risk. The premium becomes a risk signal the buyer reads.
  4. Diligence flag. An acquirer reads the regulatory page in diligence and flags US-readiness risk before any technical flag. The deal prices lower or stalls.
  5. Channel partners. US distributors decline to carry the line until a US framework status is declared. The team reads the decline as a margin negotiation. It is a regulatory-readiness sort.

Place the US frame next to the EU frame. Declare status. Stop hiding the work.

Stage one: review the regulatory posture across every US surface. Read the product pages, the regulatory page, the RFP responses, the spec sheets, the deck, and the footer. Map the gap: where is CE named, where is the US framework missing, where is the US status declared, where is the EU AI Act posture missing on AI-touching lines. The output is a per-surface gap list, not generic advice. US regulatory filing work itself sits with US counsel and the firm's regulatory consultant, not with us.

Stage two: rebuild the regulatory posture page and the per-product compliance block. Name the US framework explicitly per product line: FDA 510(k), NRTL listing, FCC Part 15, EPA registration, FedRAMP ATO, CMMC posture, ITAR or EAR classification, where applicable. Declare status: registered with number, in process with filing date, planned with named timeframe, or not applicable with a one-line reason. Place the US frame and the EU frame side by side. The CE mark moves out of the footer and onto a compliance block paired with the US-side claim.

Stage three: rebuild the RFP-response regulatory section and brief the BD seat. Replace the regulatory section in the response template with the US framework cross-reference. Train the BD writers on the declared-status language. Confirm the regulatory posture statement on the deck. The buyer now reads a US-ready posture above the fold and the same EU-side strength on the inside.

This work fits inside a Market Entry Sprint (six to ten weeks, regulatory posture page plus per-product compliance blocks plus RFP-response regulatory section plus deck), a Cross-Border Build (three to six months, full multi-channel US presence including regulatory presentation), or a Group Partnership (monthly retainer, twelve-month minimum, for groups with multiple regulated product lines). Public prices are not listed; fit, scope, and sequence are set after the inquiry review.

Before rebuild (EU-only presentation)After rebuild (paired EU and US presentation)
Footer: CE, RoHS, REACH, GS, ISO 13485 onlyFooter paired: EU marks left, US framework right with declared status
Medical device page: MDR 2017/745 conformity statementMDR 2017/745 paired with FDA 510(k) status and clearance number where issued
SaaS page: GDPR, ISO 27001, EU data-residency onlyGDPR and ISO 27001 paired with FedRAMP ATO status, SOC 2 Type II date, CMMC posture
Radio module: CE RED conformity onlyCE RED paired with FCC Part 15 ID and Industry Canada IC ID
Industrial electrical: CE LVD onlyCE LVD paired with NRTL listing on OSHA NRTL list with file number
RFP response names EU conformity but no US statusRFP response names US status, EU conformity, owner, and next filing step
Sequence

Review first. Posture page rebuild second. Per-product blocks third. RFP-response regulatory section fourth. The EU-market site stays as it is. The US-facing posture sits as a paired statement, not a footer mark.


US

"The CE mark is not the red flag. The red flag is a US buyer trying to find the US status and finding only the EU mark."

House reading · Regulatory posture review

Frequently asked.

The reader sees a firm that has done European regulatory work and not US regulatory work. The CE mark by itself does not signal US readiness. It signals EU readiness. Without a paired US claim, the same footer reads as evidence the firm has not seriously entered the US regulatory frame. The fix is naming the US path explicitly: FDA 510(k) where it applies, NRTL listing where electrical, FCC Part 15 where wireless, EPA where chemical or emissions, with status declared as registered, in process, or planned within a named timeframe.

It carries weight as a signal of engineering and quality-system discipline. It does not carry regulatory weight. The US regulatory regime is a separate frame: FDA for medical devices, FCC for radio and unintentional radiators, NRTL OSHA listings for workplace electrical equipment, EPA for emissions and chemicals, NHTSA for vehicle safety, FAA for aerospace components, NIST and FIPS for federal IT. Showing CE alongside the US frame, with the US side declared, reads as proportionate. Showing CE alone reads as unfinished.

The consultant is necessary for the filing work and falls outside our scope. The placement and communication problem still has to be solved by the firm. The consultant prepares the 510(k) or the NRTL submission. The firm decides how the US regulatory posture is named on the website, in the deck, in the quote, in the RFP response. A correct US filing presented in a German-register footer still reads as not-yet-US-ready. The fix is communication architecture on top of regulatory work, not one or the other.

No. Every regulated US sector runs the same sort. SaaS and cloud face FedRAMP and SOC 2 expectations from US federal and large-enterprise buyers. Defense-adjacent IT faces CMMC and DFARS 252.204-7012. Hardware faces FCC, NRTL, and UL. Chemicals face EPA. Industrial automation faces OSHA and UL standards. Vehicle systems face NHTSA. A German engineering firm presenting only EU-side compliance in any of these sectors reads as not-yet-cleared in the US frame, regardless of vertical.

It reads for named US frameworks on the page. CE without a paired US claim parses as low US-regulatory-readiness. FDA 510(k), NRTL listing, FCC Part 15, FedRAMP, CMMC, ITAR or EAR classification, where applicable, parse as readiness signals. Footer placement is parsed too. EU mark above the fold and US frame absent reads as priority order.

US buyers reading the firm's compliance posture may also read for EU AI Act readiness on AI-touching product lines. This is one of the cases where the EU posture and the US sale are linked: a firm with strong EU AI Act posture and a clear US AI deployment posture reads as serious in both. A firm with neither posture stated reads as incomplete in both markets.

A Market Entry Sprint rebuilds the regulatory posture page, the product surfaces, the RFP-response language and the deck inside six to ten weeks. A Cross-Border Build covers full multi-channel US presence including regulatory presentation, paid landing, sales enablement, and outbound register over three to six months. A Group Partnership runs ongoing rebuild and run on monthly retainer with a twelve-month minimum. Public prices are not listed; fit, scope, and sequence are set after the inquiry review.

Inquiry through the contact form. Share the current US-facing site, the regulatory or compliance page, the most recent US RFP response, the product spec sheets, and a representative DACH spec sheet for comparison. Response within one business day.

What this work does not include.

No legal services. No US entity formation. No E-2, L-1, EB-5, or O-1 visa work. No US tax structuring. No US banking introductions. No fiduciary services. No regulatory licensing or filing as a legal or regulated act. No 510(k) preparation. No NRTL submission. No FedRAMP package authoring. No CMMC certification work. No ITAR or EAR classification opinion. No IP filing. No contract drafting. No M&A transaction work. The regulatory filing work belongs with US regulatory counsel and the firm's regulatory consultants. The firm works on how the regulatory posture is named, placed, and read on US-facing surfaces, alongside that counsel, and defers all filing decisions to them.

Buyer path, failing layer, and implementation route.

This page matters when a real company enters a new market and the buyer reads the company, proof, offer, price, channel, or follow-up wrong.

Buyer actionUse this page when an action is not happening: inquiry, quote request, RFQ, proposal, purchase, appointment, booked job, or sales handoff.
Wrong market readThe new market may misread category, proof, language, channel fit, pricing posture, or the seriousness of follow-up.
Proof and trustThe inspection step is to find which commercial layer breaks before adding more campaigns, pages, distributors, or sales activity.
Next moveIf the failing layer is commercial, move toward /engagements/ or /contact/#inquiry.

Start the inquiry →

If the US buyer keeps asking for the 510(k) or the NRTL or the FedRAMP, the absence is closing the deal.

Share the regulatory page, the product spec sheets, and the most recent US RFP response. Response within one business day.

Start the inquiry
Start the inquiry